These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15838657)

  • 41. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Chi K; Kuhn J; Gleave M; Patnaik A; Takimoto C; Schwartz G; Thompson I; Berg K; D'Aloisio S; Murray N; Frankel SR; Izbicka E; Rowinsky E
    Clin Cancer Res; 2005 May; 11(10):3854-61. PubMed ID: 15897586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
    Tannock IF; de Wit R; Berry WR; Horti J; Pluzanska A; Chi KN; Oudard S; Théodore C; James ND; Turesson I; Rosenthal MA; Eisenberger MA;
    N Engl J Med; 2004 Oct; 351(15):1502-12. PubMed ID: 15470213
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
    Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
    Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
    J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
    Berry WR
    Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Docetaxel (Taxotere) and vinorelbine in the treatment of non-small cell lung cancer.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Papadakis E; Bouros D; Apostolopoulou F; Georgopoulou T; Agelidou M; Souglakos J; Halkiadakis G; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-9-S14-14. PubMed ID: 9335517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
    BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
    Dagher R; Li N; Abraham S; Rahman A; Sridhara R; Pazdur R
    Clin Cancer Res; 2004 Dec; 10(24):8147-51. PubMed ID: 15623588
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study.
    Cals L; Nouyrigat P; Valenza B; Pedinelli FJ; Juin P
    Oncology; 2004; 67(3-4):257-61. PubMed ID: 15557787
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
    Shimazui T; Kawai K; Miyanaga N; Kojima T; Sekido N; Hinotsu S; Oikawa T; Joraku A; Akaza H
    Jpn J Clin Oncol; 2007 Aug; 37(8):603-8. PubMed ID: 17673473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
    Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer.
    Sweeney CJ; Monaco FJ; Jung SH; Wasielewski MJ; Picus J; Ansari RH; Dugan WM; Einhorn LH
    Ann Oncol; 2002 Mar; 13(3):435-40. PubMed ID: 11996476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
    Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
    Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
    Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 May; 95(7):963-8. PubMed ID: 15839914
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study.
    Tralongo P; Bollina R; Aiello R; Di Mari A; Moruzzi G; Beretta G; Mauceri G; Conti G
    Tumori; 2003; 89(1):26-30. PubMed ID: 12729357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
    Oudard S; Caty A; Humblet Y; Beauduin M; Suc E; Piccart M; Rolland F; Fumoleau P; Bugat R; Houyau P; Monnier A; Sun X; Montcuquet P; Breza J; Novak J; Gil T; Chopin D
    Ann Oncol; 2001 Jun; 12(6):847-52. PubMed ID: 11484963
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
    Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.